gdc-0425
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2011 (NCT01359696)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase Chk1INHIBITOR
CHEK1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCN1CCC(Oc2c(C#N)ncc3[nH]c4ncccc4c23)CC1- Mol. weight
- 321.38 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314388 ↗
- ChEMBLCHEMBL3545007 ↗
Also known as
- gdc-0425
- gdc-0425
- gdc-0425
- rg-7602
- rg-7602
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01359696 | Phase 1 | Jul 11, 2011 | Genentech |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Genentech | For profit | 1 | 1 | 1 | 2011 |
1 organizations
Page 1 / 1